Circadian genes and risk of prostate cancer in the prostate cancer prevention trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1098-2744|57|3|462-466

ISSN： 0899-1987

Source： Molecular Carcinogenesis, Vol.57, Iss.3, 2018-03, pp. : 462-466

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prostate Cancer Disparities throughout the Cancer Control Continuum

By Borysova Meghan E.   Sultan Dawood H.   Chornokur Ganna   Dalton Kyle J.   Troutman Adewale  

Social Sciences, Vol. 2, Iss. 4, 2013-11 ,pp. : 247-269

MDPI

Access to resources Recommend Favorite

Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population

By  

Molecular Carcinogenesis, Vol. 54, Iss. 8, 2015-08 ,pp. : 632-641

John Wiley & Sons Inc

Access to resources Recommend Favorite

Androgen receptor profiling predicts prostate cancer outcome

By  

EMBO Molecular Medicine, Vol. 7, Iss. 11, 2015-11 ,pp. : 1450-1464

John Wiley & Sons Inc

Access to resources Recommend Favorite

Does a decision aid for prostate cancer affect different aspects of decisional regret, assessed with new regret scales? A randomized, controlled trial

By  

Health Expectations (Electronic), Vol. 19, Iss. 2, 2016-04 ,pp. : 459-470

John Wiley & Sons Inc

Access to resources Recommend Favorite

Decision aid use during post‐biopsy consultations for localized prostate cancer

By  

Health Expectations (Electronic), Vol. 21, Iss. 1, 2018-02 ,pp. : 279-287

John Wiley & Sons Inc

Access to resources Recommend Favorite